Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
How a cocktail of rogue storms and climate chaos unleashed deadly flooding across Asia - 2Becoming amazing at Systems administration: Individual and Expert Tips
- 3The many ways that baking is winter therapy. With a delicious ending
- 4South Korea launches Earth-observation satellite on homegrown Nuri rocket
- 537 Things Just Individuals Experiencing childhood during the 80s Will Comprehend
- Manual for Financial plan Agreeable PC
- IDF carried out mission to locate former hostage Avera Mengistu a day before Oct. 7
- $2,000 tariff rebate checks? 50-year mortgages? Making sense of Trump's new 'affordability' proposals.
- 6 Web-based Staple Help You Can Trust
- A NASA spacecraft orbiting Mars may be dead
- Step by step instructions to Look at Compact disc Rates: A Thorough Aide
- Find the Interesting Universe of Computerized reasoning: the Capability of man-made intelligence
- Study shows no clear link between low-fat dairy and dementia risk
- How will the universe end?
